RT Journal Article
SR Electronic
T1 COVID-19 effective reproductive ratio determination: An application, and analysis of issues and influential factors
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.15.20154039
DO 10.1101/2020.07.15.20154039
A1 Baibás, Luis Alfredo Bautista
A1 Conesa, Mario Gil
A1 Caravaca, Gil Rodríguez
A1 Baibás, Blanca Bautista
YR 2020
UL http://medrxiv.org/content/early/2020/08/12/2020.07.15.20154039.abstract
AB An essential indicator of COVID-19 transmission is the effective reproduction number (Rt), the number of cases which an infected individual is expected to infect at a particular point in time; curves of the evolution of Rt over time (transmission curves) reflect the impact of preventive measures and whether an epidemic is controlled. We have created a Shiny/R web application (https://alfredob.shinyapps.io/estRO/) with user-selectable features: open data sources with daily COVID-19 incidences from all countries and many regions, customizable preprocessing options (smoothing, proportional increment, backwards distribution of negative corrections, etc), different MonteCarlo-Markov-Chain estimates of the generation time or serial interval distributions and state-of-the-art Rt estimation frameworks (EpiEstim, R0). We have analyzed the impact of these factors in the obtained transmission curves. We also have obtained curves at the national and sub-national level and analyzed the impact of epidemic control strategies, superspreading events, socioeconomic factors and outbreaks.We conclude that country wealth and, to a lesser extent, mitigation strategies, were associated with poorer epidemic control. Dataset quality was an important factor, and sometimes dictated the necessity of time series smoothing. We couldn’t find conclusive evidence regarding the impact of alleged superspreading events. In the reopening phase, outbreaks had an impact on transmission curves. This application could be used interactively as a tool both to obtain transmission estimates and to perform interactive sensitivity analysis.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNot applicable.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No oversight body was needed since this study deals with COVID-19 open data.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used here is already publicly available. https://alfredob.shinyapps.io/estR0/